On this episode, Dennis Walker talks with Aaron Paul Orsini, the co-founder of Autistic Psychedelic Community, author of Autism on Acid, and producer of the recently released, therapy-friendly instrumental music album “Psychedelic Symphonies."
Similar Posts
Creating Inclusive KAP Training Practices with TRIPP Founder Jennifer Montjoy
In this episode, Swati Sharma sits down with Jennifer Montjoy, Founder of Transpersonal Research Institute of Psychotherapeutic Psychedelics also known as TRIPP.
Is investing in PSYCHEDELIC STOCKS the future🍄? (Intro to The Psychedelic Investor)
So why do we think psychedelic stocks are the next big thing? Here is the story of how the Joe Rogan Podcast led one Tesla Investor to investing in psychedelic stocks and starting the channel: The Psychedelic Investor 🍄.
From MindMed (MMED/MMEDF) to Compass Pathways (CMPS) and other growth stocks in the psychedelic landscape, we aim to cover the developments in the psychedelic stocks field. Our main goal is creating a community where information can be shared and we can learn each other. So is investing in psychedelic stocks the future? Guess we’ll find out soon enough: together.
👍Like & Subscribe to join us on our journey to achieving Alpha Returns
Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#PsychedelicStocks #MindMed #JoeRogan #Tesla #ShroomStocks #MMED #CMPS #ThePsychedelicInvestor
Interview With Rabbi Zac Kamenetz
Founder and CEO of Shefa, and Co-Founder of the Jewish Psychedelic Summit, Rabbi Zac Kamenetz, speaks about the upcoming summit and the connection between Judaism and psychedelics.
HUGE News on Compass Pathways (CMPS) Patents [ + Updates on MINDMED (MMED/MMEDF) ENBI, CYBN & MYCOF]
In today’s episode of “This Week in Psychedelic Stocks”, we have News on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Cybin (CYBN) & Mydecine (MYCO / MYCOF).
I covered some breaking news on MindMed yesterday in our impromptu episode on the MindMed stock being added to the FTSE so that MMED / MMEDF news is not in this episode. However, this wasn’t the only big news this week. Compass Pathways (CMPS) received not one but 2 new patents and surely, some of you might find this news worth discussing…
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Timestamps:
0:00 – Intro
0:55 – Psilocybin to treat OCD?
5:28 – The Psychedelic Industry worth $300 Billion by 2027?
8:24 – MindMed stock news ( MMED / MMEDF / MMQ)
11:39 – Compass Pathways stock news ( CMPS)
15:07 – Entheon Biomedical Corp stock news ( ENBI / ENTBF )
19:25 – Cybin stock news ( CYBN / CLXPF )
22:52 – Mydecine stock new ( MYCO / MYCOF )
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #CompassPathways #Entheon
Top 5 Psychedelics Milestones In 2021 & What To Expect in 2022 | Science, Funding, Stocks & More
The psychedelic medicines industry had a revolutionary year in 2021. At the start of the year, there were only a couple of publicly traded companies, but by the end of it, there were dozens. These companies are racing to answer questions such as: Can psychedelics cure depression? Can psychedelic treat anxiety? And, can psychedelics help with mental health?
Though the answers to these questions have not been proven 100%, after 2021, it does appear more likely than not that the answer to some of these at least, is yes. In this video, we will recap some of the most significant milestones of the psychedelics industry in 2021, and end it with what I am looking forward to in the new year.
The first big story of 2021 was the IPOs. Though MindMed (MNMD/MMED) and Compass Pathways (CMPS) went public in 2020, companies such as Field Trip Health (FTRP), Numinus Wellness (NUMI), atai Life Sciences (atai), Cybin Corp (CYBN), and dozens of others joined them in 2021. Add to this the launch of ETFs such as the Horizons Psychedelics ETF (PSYK) and the Advisor Shares Psychedelics ETF (PSIL), and 2021 was a huge year for the advent of public companies in the psychedelic medicines space.
The next big story was uplistings. Not all stock markets are created equal. In order to have the prestigious needed to attract serious money, companies need to be on exchanges such as the Nasdaq, NYSE, and the TSX. In 2021 we saw MindMed, Numinus, Field Trip, Cybin, and more join the big boys league.
Third, was funding. Psychedelic companies are for the most part biotech companies. In order to get a new drug through the clinical trial process, it takes hundreds of millions of dollars. This year we saw atai, Compass, MindMed, Cybin, and Field Trip, among others, raise over a billion dollars for the industry. This will sustain them for years to come.
And finally, 2021 saw a few high-profile clinical trials. The most significant was the MAPS Phase 3 clinical trial, which treated PTSD with MDMA-assisted therapy. The results of this trial were earth-shattering. Equally important was the Compass phase 2b trial, treating treatment-resistant depression with Psilocybin.
Moving into the new year, I am excited to see more clinical trials, and I expect to see mergers in the field.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
@Psychedelic Spotlight
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Psychedelics #MindMed #Psylocybin
Interview With Dr. Gorman
In this episode of the Psychedelic Spotlight podcast, we speak with Dr. Ingmar Gorman who is the Co-Founder and Lead Trainer at Fluence, and a Principal Investigator for the Multidisciplinary Association for Psychedelic Studies (“MAPS”).ya Health’s Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.